> PT-141 10 mg · Lumera Labs
For laboratory research use only. Not for human consumption. Free cold-chain shipping over $90 CAD · Ships from Kelowna, BC
Free cold-chain shipping over $200 CAD · Ships from Kelowna, BC
Track order My account Wishlist Contact
LUMERA LABS
Home / Catalog / Neuro / PT-141 10 mg
PT-141 10 mg vial
4.6 · 61 researcher reviews
Cognitive · Melanocortin agonist

PT-141

SKU LUM-PT141-10 · C₅₀H₆₈N₁₄O₁₀ · 1025.18 g/mol · CAS 189691-06-3

A cyclic heptapeptide melanocortin-receptor agonist (MC4R-selective). Investigated for central nervous system signaling and behavioral pharmacology.

Purity (HPLC)
≥ 99.2%
Net peptide
5.00 mg ± 2%
Endotoxin
< 0.5 EU/mg
Format
Lyophilized vial
Storage
−20 °C, desiccated
Shelf life
24 months from MFG
$90CAD / 10 mg vial
In stock · Lot 26-A031
Qty
Bulk 10+: $24 / vial
Add $200 for free cold-chain shipping
  • HPLC + MS verified per lot
  • Cold-chain to your door
  • COA bundled with shipment
  • Lot retains kept 5 years

Overview

PT-141 (bremelanotide) is a synthetic cyclic seven-residue analog of α-MSH with high affinity for the melanocortin-4 receptor (MC4R) and lower affinity for MC1R/MC3R/MC5R. It is investigated as a tool compound for central melanocortin-system pharmacology.

Each vial is lyophilized from acetate buffer, sealed under nitrogen, and shipped cold-chain at −20 °C from our Kelowna facility.

Research applications

MC4R agonism potency assays, comparative MC1-5R selectivity screens, behavioral pharmacology in rodent models, and structural studies of the melanocortin-pharmacophore.

Sold for laboratory research only. This material is not a drug, food, or cosmetic and is not intended for diagnostic, therapeutic, or recreational use.

Identity

ParameterValue
SequenceAc-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
Molecular formulaC₅₀H₆₈N₁₄O₁₀
Molecular weight1025.18 g/mol
CAS number189691-06-3
Length7 residues (cyclic)

Quality

TestSpecification
HPLC purity≥ 99.0% (lot LM-2638: 99.11%)
Mass confirmationESI-MS within 0.5 Da
Net peptide content≥ 80% by AAA
Endotoxin< 0.5 EU/mg (LAL)
Bioburden< 10 CFU/g
Residual TFA< 1.0%

Lot LM-2638

Manufactured 04 Mar 2026 · Released 11 Mar 2026 · Tested by Lumera QC, Kelowna BC. Retain samples held under storage spec for five years from release date.

Verification

MethodResult
RP-HPLC at 220 nm99.11% main peak
ESI-MS (positive)1025.2 Da (theor. 1025.18)
Amino acid analysis82.1% net peptide
LAL endotoxin< 0.05 EU/mg
Karl Fischer (water)2.8% w/w

Reconstitution

Allow vial to reach room temperature before opening (≥ 20 minutes). Reconstitute with 1.0–2.5 mL of sterile bacteriostatic water (0.9% benzyl alcohol). Inject solvent slowly down the inner wall of the vial; do not direct stream onto the lyophilized cake.

Swirl gently for 30 seconds. Do not vortex. Allow to dissolve for 5 minutes; clarity should be complete with no visible particulates.

Storage after reconstitution

Reconstituted solution is stable for 28 days at 2–8 °C in original vial. For longer storage, aliquot into low-binding tubes and hold at −80 °C; avoid repeated freeze-thaw cycles. Discard if turbidity, color change, or particulate matter is observed.

Selected references

Kingsberg SA et al. Bremelanotide for the treatment of hypoactive sexual desire disorder. Obstet Gynecol. 2019;134(5):899–908.

Hadley ME, Dorr RT. Melanocortin peptide therapeutics. Peptides. 2006;27(4):921–930.

Pfaus JG et al. The melanocortin-4 receptor agonist bremelanotide and proceptive sexual behavior. J Sex Med. 2014;11(11):2754–2767.

Citing this material

PT-141 reference standard, ≥99% (HPLC), Lumera Labs Inc., Cat. No. LUM-PT141-10, Lot 26-A031.

Related · Cognitive axis

Often paired in studies.

View catalog →
GLP-1/GIP · Metabolic

Tirzepatide

10 mg · ≥ 99.3%

$40 CADView →
Tri-agonist · Metabolic

Retatrutide

10 mg · ≥ 99.2%

$85 CADView →
Metabolic

Cagrisema

10 mg · ≥ 99.1%

$72 CADView →
Growth axis

AOD-9604

10 mg · ≥ 99.0%

$36 CADView →

Why Lumera

  • Janoshik Analytical HPLC ≥ 99.2% on this lot
  • LC-MS identity confirmed before release
  • LAL endotoxin below detection limit
  • Cold-chain shipped −20°C from Kelowna, BC
Background research

What the literature says about Pt 141.

Mechanism

Pt 141 is a melanocortin receptor agonist, classified within the central nervous system signaling pathway. Structurally it is a synthetic α-MSH analog. Bremelanotide (PT-141) is a synthetic cyclic 7-residue melanocortin agonist with affinity for the MC3R and MC4R subtypes. Diamond et al. (2006) characterized its central effects in animal and clinical pharmacology.

In an in-vitro setting, Pt 141 interacts with its target receptor(s) at low-nanomolar affinities under standard binding-assay conditions. Reconstitution should be performed in sterile bacteriostatic water at the working concentration your protocol specifies; the lyophilized vial is sealed under nitrogen and stable at −20 °C until reconstituted.

Common research applications

  • In-vitro receptor-binding and dose-response screens against the central nervous system signaling target panel.
  • Comparative pharmacology against related class members and previously published reference standards.
  • Time-course studies leveraging Pt 141's known stability profile.
  • Cross-batch HPLC fingerprint comparison against the lot-specific COA we publish for every release.

Storage & handling

Pt 141 arrives lyophilized at −20 °C in cold-chain insulated packaging. On receipt, transfer immediately to a −20 °C freezer. Once reconstituted, store at 2-8 °C and use within the window noted on the lot's COA. Avoid repeated freeze-thaw cycles.

References

  1. Diamond LE et al. J Sex Med. 2006;3(4):628-38.
  2. Pfaus JG et al. Pharmacol Biochem Behav. 2007;87(1):65-72.
  3. Kingsberg SA et al. Obstet Gynecol. 2019;134(5):899-908.

For laboratory research only. Pt 141 is sold strictly as an in-vitro reference standard. It is not approved for human or veterinary use by Health Canada or the FDA.

$90 CAD